Thermo Fisher Scientific Risankizumab Humanized Recombinant Human Monoclonal Antibody

Applications

• ELISA (ELISA): Assay-dependent

Product Specifications

Product Specific Information

• Endotoxin level: < 0.01 EU/µg (LAL method)
• Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
• Store at 2–8°C for one week.
• Store at -20 to -80°C for up to twelve months from the date of receipt.

Target Information

Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) that selectively binds to interleukin 23 (IL-23).
It was approved by the FDA on April 23, 2019 (as SKYRIZI) for the treatment of moderate-to-severe plaque psoriasis in adults eligible for systemic therapy or phototherapy.
This pharmaceutical was developed through collaboration between Boehringer Ingelheim and Abbvie.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.